Track topics on Twitter Track topics that are important to you
Pharmaceutical company Boehringer Ingelheim has initiated a European and North American Phase IIa trial in non-alcoholic steatohepatitis (NASH) of investigational drug candidate BI 1467335 (formerly known as PXS-4728A), acquired from fellow pharma company Pharmaxis in May 2015.
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in Western industrialised nations; its more serious form, NASH, is particularly prevalent amongst patients with type 2 diabetes. NASH is a major cause of liver fibrosis and cirrhosis and is an area of high unmet medical need, with no treatments currently available.
In 2016 Boehringer Ingelheim obtained Fast Track designation from the US FDA for the development of BI 1467335 in NASH. The compound is an oral inhibitor of amine oxidase, copper containing 3 (AOC3), and works by blocking leucocyte adhesion and tissue infiltration in inflammatory processes underlying NASH.
The new Phase IIa trial is a multicentre, double-blind design in 150 patients with clinical evidence of NASH. The primary objectives are to establish proof of clinical principle, investigate suitable dosing and evaluate the safety of BI 1467335. Patients will be randomised to either one of four dosages of BI 1467335 or to placebo for a 12-week treatment period. A subsequent Phase IIb study will seek to confirm and extend these findings.
Original Article: Boehringer Ingelheim initiates Phase IIa study of liver disease drugNEXT ARTICLE
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...